COVID-19 antibody / German Cancer Research Center, University Hospital Tuebingen, Thorax Clinic Heidelberg, Singleron Biotech - LARVOL DELTA

[VIRTUAL] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (ESMO Asia 2020) - P3 | "No confirmed or suspected COVID-19 AEs were reported. Funding: F. Hoffmann-La Roche, Ltd. Clinical trial identification: NCT02425891."

Clinical • P3 data • Breast Cancer • Infectious Disease • Liver Cancer • Novel Coronavirus Disease • Oncology • Pain • Solid Tumor • Triple Negative Breast Cancer • PD-L1

[VIRTUAL] Student-initiated teaching in the elective track "Interdisciplinary Oncology" at the Medical Faculty Heidelberg (DGHO 2020) - "Due to the COVID-19 pandemic, both seminars were held virtually during the summer term 2020. The student-initiated seminars have a high participation rate. This indicates that student-initiated teaching initiatives should be encouraged and implemented into medical education to strengthen interest in basic and translational research."

Infectious Disease • Novel Coronavirus Disease • Oncology

[VIRTUAL] Student-initiated teaching in the elective track "Interdisciplinary Oncology" at the Medical Faculty Heidelberg (DGHO 2020) - "Due to the COVID-19 pandemic, both seminars were held virtually during the summer term 2020. The student-initiated seminars have a high participation rate. This indicates that student-initiated teaching initiatives should be encouraged and implemented into medical education to strengthen interest in basic and translational research."

Infectious Disease • Novel Coronavirus Disease • Oncology

Testing for COVID-19 Infection in Asymptomatic Persons (clinicaltrials.gov) - P; N=500; Not yet recruiting; Sponsor: German Cancer Research Center

New trial